Evidence map›Paper›PMID 33093687›Full record

ArticleSynthetic communications2019

The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor.

Jatinder Kaur, Atul Bhardwaj, Bruce J Melancon, Brian S J Blagg

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. FeRSC advances · 2023
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jatinder KaurWarren Family Research Center for Drug Discovery and Development, Department of Chemistry and Biochemistry,University of Notre Dame, Notre Dame, Indiana, USA.
Atul BhardwajWarren Family Research Center for Drug Discovery and Development, Department of Chemistry and Biochemistry,University of Notre Dame, Notre Dame, Indiana, USA.
Bruce J MelanconWarren Family Research Center for Drug Discovery and Development, Department of Chemistry and Biochemistry,University of Notre Dame, Notre Dame, Indiana, USA.
Brian S J BlaggWarren Family Research Center for Drug Discovery and Development, Department of Chemistry and Biochemistry,University of Notre Dame, Notre Dame, Indiana, USA.
University of Notre Dame · US

Funding

Development of Hsp90 inhibitors for the treatment of cancerR01CA167079 · NCI · UNIVERSITY OF NOTRE DAME · PI BLAGG, BRIAN S J · 2012 to 2016
$1.5M
NCI NIH HHS R01 CA167079
6 · The paper itself

Abstract

AT13387 is an orally bioavailable clinical candidate developed to inhibit theheat shock protein 90 (Hsp90). This article describes a modified synthetic route for the multi-gram production of AT13387 in 46% overall yield. The modified synthetic route is short, avoids stringent reaction conditions and difficult purifications, which led to increase in an overall yield.

Indexed as

AT13387Cost-effective synthetic routeHsp90Iso-indolineProteostasis

Identifiers

PMID33093687
PMCPMC7577423
OpenAlexW2940589045

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.